Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Executive Compensation

On September 28, 2025, the Board of Directors of Insight Molecular Diagnostics Inc. (the "Company") approved the grant of stock options to certain employees, including Josh Riggs, President and Chief Executive Officer; Andrea James, Chief Financial Officer; Dr. Ekkehard Schütz, Chief Science Officer; and James Liu, Vice President Accounting, Controller, Treasurer and Principal Accounting Officer under the Company's Amended and Restated 2018 Equity Incentive Plan (the "Plan"). Mr. Riggs received options to purchase 400,000 shares of common stock, each of Ms. James and Dr. Schütz received options to purchase 235,000 shares of common stock and Mr. Liu received options to purchase 18,000 shares of common stock. The options will vest over a three-year period, with one-third vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments over the following two years, subject to continued service. The exercise price of the options is $3.33, the closing price of the Company's common stock on the trading day immediately prior to the grant date, and the options are subject to the terms and conditions of the Plan and award agreements.

Employment Agreement Amendment

On September 29, 2025 (the "Effective Date"), the Company entered into an amendment to employment agreement with Dr. Schütz, effective as of the Effective Date (the "Employment Agreement Amendment"), which amends Mr. Schütz's existing employment agreement with the Company, dated May 20, 2024 (the "Existing Employment Agreement"). Except as provided herein, all other terms of the Existing Employment Agreement remain the same.

The Employment Agreement Amendment amends the term of the Existing Employment Agreement from four years after the effective date of the Existing Employment Agreement to instead continue until such time as Dr. Schütz's Existing Employment Agreement is terminated in accordance with the terms of the Existing Employment Agreement.

The foregoing description of the Employment Agreement Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.